Clinical Trial Update: Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL [Phase 2]

View source ↗

Summary

The Phase 2 open-label safety and efficacy study to determine the optimal single-dose regimen of Ambisome for visceral leishmaniasis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Visceral Leishmaniasis

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: Drugs for Neglected Diseases | Conditions: Visceral Leishmaniasis | Phase 2 | Status: TERMINATED